Objective To investigate the value of Charlson comorbidity index (CCI) in predicting the short- and long-term risks of death in patients with acute-on-chronic liver failure (ACLF).Methods A total of 317 patients with ACLF who attended The First Hospital of Lanzhou University from December 1, 2016 to December 1, 2021 were enrolled, and according to their prognosis, they were divided into death group with 169 patients and survival group with 148 patients. The two groups were analyzed in terms of clinical data and follow-up data. The group t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. The univariate and multivariate Cox proportional-hazards regression model analyses were used to investigate the influencing factors for the prognosis of ACLF patients. The Kaplan-Meier method was used to plot survival curves, and the Log-rank test was used for comparison of survival time between patients with different CCI scores. The receiver operating characteristic (ROC) curve was used to evaluate the performance of CCI and other indices in assessing the prognosis of ACLF patients.Results Among the 317 patients, there were 225 (71.0%) male patients. There were significant differences between the death group and the survival group in age, hemoglobin, white blood cell count, total bilirubin, albumin, Model for End-Stage Liver Disease (MELD) score, prothrombin time activity, CCI, age-adjusted Charlson co-morbidity index (ACCI), and follow-up time (all P < 0.05). The multivariate Cox regression analysis showed that the CCI (hazard ratio [HR]=1.351, 95% confidence interval [CI]: 1.112-1.641, P=0.002), ACCI (HR=1.200, 95%CI: 1.011-1.423, P=0.037), and MELD score (HR=1.076, 95%CI: 1.054-1.099, P < 0.001) were independent risk factors for the prognosis of ACLF patients. Based on CCI score, the patients were divided into CCI ≤4 group with 167 patients, CCI=5 group with 64 patients, and CCI ≥6 group with 86 patients, with a 3-year mortality rate of 26.5%, 83.2%, and 96.9%, respectively, and there was a significant difference in survival time between any two groups after 3 years of follow-up and at the time of follow-up till September 2022 (all P < 0.001). CCI, ACCI, and MELD scores had an area under the ROC curve of 0.845, 0.811, and 0.790, respectively, in predicting the prognosis of ACLF patients.Conclusion As commonly used comorbidity assessment indices, CCI and ACCI scores have certain value in evaluating the short- and long-term prognosis of ACLF patients.
BAJAJ JS, O'LEARY JG, LAI JC, et al. Acute-on-chronic liver failure clinical guidelines[J]. Am J Gastroenterol, 2022, 117(2): 225-252. DOI: 10.14309/ajg.0000000000001595.
[2]
ARROYO V, MOREAU R, JALAN R. Acute-on-chronic liver failure[J]. N Engl J Med, 2020, 382(22): 2137-2145. DOI: 10.1056/NEJMra1914900.
[3]
CHARLSON ME, POMPEI P, ALES KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J]. J Chronic Dis, 1987, 40(5): 373-383. DOI: 10.1016/0021-9681(87)90171-8.
[4]
CHARLSON M, SZATROWSKI TP, PETERSON J, et al. Validation of a combined comorbidity index[J]. J Clin Epidemiol, 1994, 47(11): 1245-1251. DOI: 10.1016/0895-4356(94)90129-5.
[5]
TAKEMURA K, TAKENAKA Y, ASHIDA N, et al. Age-adjusted Charlson Comorbidity Index predicts prognosis of laryngopharyngeal cancer treated with radiation therapy[J]. Acta Otolaryngol, 2017, 137(12): 1307-1312. DOI: 10.1080/00016489.2017.1362112.
[6]
BOAKYE D, WALTER V, JANSEN L, et al. Magnitude of the age-advancement effect of comorbidities in colorectal cancer prognosis[J]. J Natl Compr Canc Netw, 2020, 18(1): 59-68. DOI: 10.6004/jnccn.2019.7346.
[7]
BAGNI K, CHEN IM, JOHANSEN AZ, et al. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer[J]. Eur J Cancer Care (Engl), 2020, 29(3): e13219. DOI: 10.1111/ecc.13219.
[8]
SARICI A, AR MC, YOKUS O, et al. The impact of transfusion burden and comorbidities on the prognosis of patients with myelodysplastic syndromes[J]. Transfus Apher Sci, 2020, 59(5): 102845. DOI: 10.1016/j.transci.2020.102845.
[9]
QU WF, ZHOU PY, LIU WR, et al. Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection[J]. Ann Transl Med, 2020, 8(7): 487. DOI: 10.21037/atm.2020.03.23.
[10]
GHABRIL M, GU J, YODER L, et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury[J]. Gastroenterology, 2019, 157(5): 1245-1252. DOI: 10.1053/j.gastro.2019.07.006.
[11]
SHINKAWA H, TANAKA S, TAKEMURA S, et al. Predictive value of the age-adjusted Charlson comorbidity index for outcomes after hepatic resection of hepatocellular carcinoma[J]. World J Surg, 2020, 44(11): 3901-3914. DOI: 10.1007/s00268-020-05686-w.
[12]
Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
KAHL A, DU BOIS A, HARTER P, et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer[J]. Ann Surg Oncol, 2017, 24(12): 3692-3699. DOI: 10.1245/s10434-017-6079-9.
[14]
BECKER C, DAHLEM K, LANGE K, et al. Predictive value of comorbidity and anemia on outcome in patients with sinonasal carcinoma[J]. J Craniomaxillofac Surg, 2018, 46(8): 1373-1378. DOI: 10.1016/j.jcms.2018.05.009.
[15]
FORMIGA F, MORENO-GONZALEZ R, CHIVITE D, et al. High comorbidity, measured by the Charlson Comorbidity Index, associates with higher 1-year mortality risks in elderly patients experiencing a first acute heart failure hospitalization[J]. Aging Clin Exp Res, 2018, 30(8): 927-933. DOI: 10.1007/s40520-017-0853-1.
[16]
FRACCARO P, KONTOPANTELIS E, SPERRIN M, et al. Predicting mortality from change-over-time in the Charlson Comorbidity Index: A retrospective cohort study in a data-intensive UK health system[J]. Medicine (Baltimore), 2016, 95(43): e4973. DOI: 10.1097/MD.0000000000004973.
[17]
RATTANASOMPATTIKUL M, FEROZE U, MOLNAR MZ, et al. Charlson comorbidity score is a strong predictor of mortality in hemodialysis patients[J]. Int Urol Nephrol, 2012, 44(6): 1813-1823. DOI: 10.1007/s11255-011-0085-9.
[18]
LI H, ZHENG J, CHEN L, et al. The scoring systems in predicting short-term outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Ann Palliat Med, 2020, 9(5): 3048-3058. DOI: 10.21037/apm-20-608.
[19]
XU Y, HUANG XP, CHEN L, et al. Value of high-density lipoprotein cholesterol in evaluating the severity and prognosis of hepatitis B virus-associated acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(7): 1632-1635. DOI: 10.3969/j.issn.1001-5256.2021.07.030.
XU X, HOU Z, XU Y, et al. The dynamic of platelet count as a novel and valuable predictor for 90-day survival of hepatitis B virus-related acute-on-chronic liver failure patients[J]. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101482. DOI: 10.1016/j.clinre.2020.06.008.
[21]
CHAN TC, LUK JK, CHU LW, et al. Validation study of Charlson Comorbidity Index in predicting mortality in Chinese older adults[J]. Geriatr Gerontol Int, 2014, 14(2): 452-457. DOI: 10.1111/ggi.12129.
CAI X, CHEN JJ, TANG DL, et al. Value of alpha-fetoprotein combined with gamma-glutamyl transpeptidase/aspartate aminotransferase ratio in diagnosis of HBV-associated hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(9): 2109-2112. DOI: 10.3969/j.issn.1001-5256.2021.09.021.
CAI X, CHEN JJ, TANG DL, et al. Value of alpha-fetoprotein combined with gamma-glutamyl transpeptidase/aspartate aminotransferase ratio in diagnosis of HBV-associated hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(9): 2109-2112. DOI: 10.3969/j.issn.1001-5256.2021.09.021.